NCT05801120

Brief Summary

The purpose of this study is to understand how ketogenic food products affect oxygen toxicity in undersea divers. Oxygen toxicity affecting the central nervous system, mainly the brain, is a result of breathing higher than normal oxygen levels at elevated pressures as can be seen in SCUBA diving or inside a hyperbaric (pressure) chamber. This is a condition that may cause a wide variety of symptoms such as: vision disturbances, ear-ringing, nausea, twitching, irritability, dizziness, and potentially loss of consciousness or seizure. Because nutritional ketosis has been used to reduce or eliminate seizures in humans, it may be beneficial to reduce oxygen toxicity as well. The investigators hope this study will provide a help to develop practical and useful methods for improving the safety of undersea Navy divers, warfighters and submariners.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
15

participants targeted

Target at below P25 for not_applicable

Timeline
Completed

Started May 2023

Shorter than P25 for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

March 24, 2023

Completed
13 days until next milestone

First Posted

Study publicly available on registry

April 6, 2023

Completed
25 days until next milestone

Study Start

First participant enrolled

May 1, 2023

Completed
8 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

January 5, 2024

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

January 5, 2024

Completed
Last Updated

May 31, 2025

Status Verified

May 1, 2025

Enrollment Period

8 months

First QC Date

March 24, 2023

Last Update Submit

May 27, 2025

Conditions

Outcome Measures

Primary Outcomes (3)

  • Change in serum acetoacetate levels.

    Assess serum ketone levels over the course of 6 hours after the ingestion of ketone food products.

    over 6 hours

  • Change in beta hydroxybutyrate levels

    over 6 hours

  • Change in acetone levels

    over 6 hours

Secondary Outcomes (1)

  • Tolerability of ketone food product ingestion measured by adverse events

    24 hours

Study Arms (3)

Ketogenic food products one time

EXPERIMENTAL

Dietary Supplement: Ketogenic food products Participants will be given a ketogenic food product prior to the hyperbaric oxygen exposure.

Dietary Supplement: Ketogenic food products

Experimental: Ketogenic food products two times

EXPERIMENTAL

Dietary Supplement: Ketogenic food products Participants will be given a ketogenic food product prior to the hyperbaric oxygen exposure.

Dietary Supplement: Ketogenic food products

Experimental: Ketogenic food products three times

EXPERIMENTAL

Dietary Supplement: Ketogenic food products Participants will be given a ketogenic food product prior to the hyperbaric oxygen exposure.

Dietary Supplement: Ketogenic food products

Interventions

Ketogenic food productsDIETARY_SUPPLEMENT

Participants will be given a ketogenic food product prior to the hyperbaric oxygen exposure.

Experimental: Ketogenic food products three timesExperimental: Ketogenic food products two timesKetogenic food products one time

Eligibility Criteria

Age18 Years - 39 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64)

You may qualify if:

  • Males \& females between 18 and 39 years old.
  • Predicted (Phase 1) VO2max ≥ 30 ml/kg/min (female) or 35 ml/kg/min (male).
  • BMI ≤ 30.0 unless VO2max and baseline exercise profile is deemed appropriate for the study by the PI.

You may not qualify if:

  • Prolonged QTc on initial ECG
  • Currently pregnant or attempting to become pregnant.
  • Have a medical history of:
  • Smoking history deemed significant by PI
  • Known significant electrolyte disorders
  • Coronary artery disease
  • Cardiac arrhythmia deemed significant by PI
  • Lung disease
  • Hypertension
  • Seizures
  • Psychiatric disorder deemed significant by PI
  • Previous pneumothorax or pneumomediastinum
  • Hypo- or hyperglycemia
  • Diabetes
  • Inability to equalize middle ear spaces during hyperbaric compression
  • +3 more criteria

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Duke University Medical Center

Durham, North Carolina, 27710, United States

Location

Study Officials

  • Bruce Derrick, MD

    Duke Health

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NON RANDOMIZED
Masking
NONE
Purpose
PREVENTION
Intervention Model
SEQUENTIAL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

March 24, 2023

First Posted

April 6, 2023

Study Start

May 1, 2023

Primary Completion

January 5, 2024

Study Completion

January 5, 2024

Last Updated

May 31, 2025

Record last verified: 2025-05

Data Sharing

IPD Sharing
Will not share

Locations